Back to Journals » Journal of Pain Research » Tapentadol for moderate to severe acute pain in children and adolescents
Journal of Pain Research
ISSN: 1178-7090
- View all (3099)
- Volume 17, 2024 (176)
- Volume 16, 2023 (350)
- Volume 15, 2022 (331)
- Volume 14, 2021 (356)
- Volume 13, 2020 (359)
- Volume 12, 2019 (330)
- Volume 11, 2018 (336)
- Volume 10, 2017 (309)
- Volume 9, 2016 (140)
- Volume 8, 2015 (93)
- Volume 7, 2014 (76)
- Volume 6, 2013 (88)
- Volume 5, 2012 (63)
- Volume 4, 2011 (44)
- Volume 3, 2010 (26)
- Volume 2, 2009 (15)
- Volume 1, 2008 (7)
Journal Articles:
- Dysmenorrhea: Therapy and Mechanism (4)
- Pain in Space: a Journey of Discovery (2)
- Complex Regional Pain Syndrome (7)
- Cancer Pain (8)
- The Future of Pain Medicine: Emerging Technologies, Treatments, and Education (1)
- Childbirth and Postpartum Pain: The Importance of Maternal Pain Control Beyond the Birth Experience (9)
- Orofacial Pain: A new US Dental Specialty. Where are we now? (2)
- Cannabis as pain medicine - the dark vs. the light side of a newly discovered treatment (1)
- Methylnaltrexone for Opioid-Induced Constipation (2)
- Tapentadol for moderate to severe acute pain in children and adolescents (11)
- Inhaled methoxyflurane for the treatment of acute trauma pain (4)
- Tapentadol: just another opioid or an innovative strong analgesic? (8)
- From acute to chronic pain: bench to bedside findings from consortium of SIMPAR young researchers (4)
- Oral Methylnaltrexone in the treatment of patients with opioid-induced constipation and noncancer pain (2)
Tapentadol for moderate to severe acute pain in children and adolescents
Medical advances and new drug development continue to reach new heights. In 1996, the United States Food and Drug Administration (FDA) approved 50 new drugs. In 2018, the FDA issued 61 approvals. However, these numbers do not reflect the progress of pharmaceutical development in 25% of the population – children. Tapentadol is a novel molecule with both mu-opioid and SNRI-like (serotonin and norepinephrine reuptake inhibitor) properties that have been shown to be effective in the treatment of acute and chronic pain in adults. This Thematic Series describes both single-blind and double-blind randomized control studies that have shown short-term benefits of this new pain medication in children. Confirmation of the short-term effects in the pediatric population from these studies allow health care providers to prescribe the oral formulation of Tapentadol with confidence in its dose, predicted effects and potential side effects.
Analgesic Drug Development for Children: A History of Shortcomings … Until Now
Dinh A, Berger A, Krane E
Journal of Pain Research 2021, 14:867-870
Published Date: 31 March 2021
Tapentadol for the Treatment of Moderate-to-Severe Acute Pain in Children Under the Age of Two Years
Eissa A, Tarau E, Beuter C, Radic T, Watson E, Sohns M, Lefeber C, Hammer GB
Journal of Pain Research 2021, 14:229-248
Published Date: 29 January 2021
Outcomes of the Pediatric Development Plan of Tapentadol
Eerdekens M, Radic T, Sohns M, Khalil F, Bulawa B, Elling C
Journal of Pain Research 2021, 14:249-261
Published Date: 29 January 2021
The challenge of developing pain medications for children: therapeutic needs and future perspectives
Eerdekens M, Beuter C, Lefeber C, van den Anker J
Journal of Pain Research 2019, 12:1649-1664
Published Date: 23 May 2019
Pharmacokinetics, safety, and efficacy of tapentadol oral solution for treating moderate to severe pain in pediatric patients
Muse D, Tarau E, Lefeber C, Sohns M, Brett M, Goldberg J, Rosenburg R
Journal of Pain Research 2019, 12:1777-1790
Published Date: 31 May 2019
First evaluation of tapentadol oral solution for the treatment of moderate to severe acute pain in children aged 6 to <18
Finkel JC, Goldberg J, Rosenburg R, Ariyawansa J, Sun T, Ochs-Ross R, Zannikos P, Zhang L, Etropolski M
Journal of Pain Research 2019, 12:1925-1936
Published Date: 28 June 2019
Population pharmacokinetic modeling to facilitate dose selection of tapentadol in the pediatric population
Watson E, Khandelwal A, Freijer J, van den Anker J, Lefeber C, Eerdekens M
Journal of Pain Research 2019, 12:2835-2850
Published Date: 14 October 2019
Efficacy and safety of multiple doses of tapentadol oral solution in the treatment of moderate to severe acute pain in children aged 2 to <18 years – a randomized, double-blind, placebo-controlled trial
Beuter C, Volkers G, Radic T, Goldberg J, van den Anker J
Journal of Pain Research 2019, 12:3099-3112
Published Date: 13 November 2019
Multiple Dose Pharmacokinetics of Tapentadol Oral Solution for the Treatment of Moderate to Severe Acute Pain in Children Aged 2 to <7 Years
Jończyk R, Beuter C, Bulawa B, Buller S, Eibl C, Elling C, Gautrois M, Rengelshausen J, Schmidt C, Thömmes G, Khalil F
Journal of Pain Research 2022, 15:3103-3114
Published Date: 30 September 2022
Population Pharmacokinetics of Tapentadol in Children from Birth to <18 Years Old
Khalil F, Choi SL, Watson E, Tzschentke TM, Lefeber C, Eerdekens M, Freijer J
Journal of Pain Research 2020, 13:3107-3123
Published Date: 24 November 2020
Tapentadol Prolonged Release for Long-Term Treatment of Pain in Children
Howard RF, Radic T, Sohns M, Eerdekens M, Waßmuth A
Journal of Pain Research 2020, 13:3157-3170
Published Date: 30 November 2020